+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Insulin Pens Market

  • ID: 5440419
  • Report
  • July 2021
  • Region: Global
  • 200 Pages
  • Future Market Insights

FEATURED COMPANIES

  • Abbott Laboratories
  • BIOCORP
  • DUKADA Aps
  • Insulcloud S.L.
  • Medtronic plc
  • Sanofi
According to the publisher, the demand for insulin pens is expected to rise considerably in the coming decade, enabling the market to surpass a valuation of US$ 30,407.5 Mn by the end of 2021.

Insulin pens are used by diabetes patients to avoid problems including cardiovascular diseases that may arise from this lifestyle-based ailment. To overcome problems related to conventional methods of insulin administration, insulin pens make the process easier and faster.

According to the WHO, approximately 1.2 million deaths were caused due to diabetes in 2019 globally. To reduce the number of deaths or sufferings due to diabetes, the development of innovative techniques and products for the treatment and maintenance of diabetes is essential.

Type 2 diabetes cases are common, but it can be prevented or delayed by a healthy diet, consistent physical activity, maintaining a standard body weight and avoiding the use of tobacco. Diabetes can be treated or managed with medicines and regular checking and treatment. Increasing focus on innovative medical products and research are increasingly driving a transition towards insulin pen by diabetes patients.

Leading manufacturers in the insulin pen market are strengthening their market position through collaborations with various health and research organizations. Governments in developed and developing countries are actively taking initiatives to encourage innovative medical products.

For instance, in November 2020, Medtronic introduced CGM integrated smart insulin delivery pen to manage multiple daily dosage insulin injections. Similarly, Insulet expanded its offering of OmipodDASH into additional countries such as Sweden, Finland, Norway, and Denmark.

Key Takeaways from Insulin Pen Services Market Study


  • Reusable insulin pens are expected to account for over 49% the global market share by 2031, supported by a growing base of environment and cost-conscious consumers.
  • Hospital pharmacies will account for 33.8% of the market share in 2031. The soaring influx of patients for treatment and intensive care support supports growth.
  • The U.S. is projected to be the fastest-growing regional market with a CAGR of 5.6% through 2021-2031 owing to the matured healthcare sector of the country.
  • The U.K. and Germany are leading markets in Europe, accounting for more than 18% and 25% in 2021.
  • China is the largest and fastest growing market in East Asia, exhibiting a 4.7% CAGR through 2031.
  • Australia is leading the Oceania market, accounting for more than 85% of insulin pen revenues in 2021.

Who is Winning?


The global insulin pen market is set to expand due to the rising prevalence of type 1 and type 2 diabetes. Leading organizations within the market are set to focus on research and development to offer an early and precise diagnosis of the ailment, besides offering effective patient care.

Some of the leading players in the insulin pen market include but are not limited to NovoNordisk A/S, Sanofi, Eli Lilly, Diamesco Co., Ltd., BigFoot Biomedical, Inc, Medtronic plc, Emperra GmbH E-Health Technologies, YpsoMed AG, and DUKADA Aps.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • BIOCORP
  • DUKADA Aps
  • Insulcloud S.L.
  • Medtronic plc
  • Sanofi
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion & Exclusion

3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends

4. Market Background
4.1. Macro-Economic Factors
4.1.1. GDP Growth Outlook
4.1.2. Global Healthcare Industry Outlook
4.1.3. Increasing Per Capita Healthcare Spending
4.1.4. Income Per Capita Outlook
4.2. Forecast Factors - Relevance & Impact
4.2.1. GDP Growth
4.2.2. Healthcare Spending
4.2.3. Prevalence of Chronic Diseases
4.2.4. COVID Pandemic
4.2.5. Product Adoption Rate
4.2.6. Regulatory Framework
4.2.7. Advancements in Technologies
4.2.8. Cost of Products
4.2.9. Key Market Player Revenue Analysis
4.2.10. Recent Key Players Activities
4.2.11. Alternative Products
4.2.12. Other Macroeconomic factors impacting insulin pen market
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity Analysis

5. Market Context
5.1. Technology Roadmap - Evolution of Safety Devices & Insulin Delivery
5.2. Key Regulatory Scenario
5.3. Value Chain Analysis
5.4. Production Analysis
5.5. Disease Epidemiology
5.6. Key Products USP Analysis

6. COVID19 Crisis Analysis
6.1. Current Economic Projection as compared to 2008 financial analysis
6.2. COVID19 and Impact Analysis
6.2.1. Revenue by Product
6.2.2. Revenue by Indication
6.2.3. Revenue by Distribution Channel
6.2.4. Revenue by Country
6.3. 2020 Market Scenario

7. Global Insulin Pen Market Volume (Units) Analysis 2016-2020 and Forecast, 2021-2031
7.1. Historical Market Volume (Units) Analysis, 2016-2020
7.2. Current and Future Market Volume (Units) Projections, 2021-2031
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis

8. Global Insulin Pen Market - Pricing Analysis
8.1. Country Pricing Analysis by Product Type
8.2. Pricing Break-up
8.2.1. Manufacturer Level Pricing
8.2.2. Distributor Level Pricing
8.3. Latin America and Middle East Average Pricing Analysis Benchmark

9. Global Insulin Pen Market Value Analysis 2016-2020 and Forecast, 2021-2031
9.1. Historical Market Value (US$ Mn) Analysis, 2016-2020
9.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031
9.2.1. Y-o-Y Growth Trend Analysis
9.2.2. Absolute $ Opportunity Analysis

10. Global Insulin Pen Market Analysis 2016-2020 and Forecast 2021-2031, by Product Type
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis by Product Type, 2016-2020
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Product Type, 2021-2031
10.3.1. Reusable Insulin Pen
10.3.1.1. Refillable Pens
10.3.1.2. Bluetooth Connected Smart Insulin Pen
10.3.1.3. USB Connected Smart Insulin Pen
10.3.1.4. Cartridge
10.3.2. Disposable Insulin Pens
10.3.3. Smart Insulin Pen Caps
10.3.4. Insulin Pump
10.4. Market Attractiveness Analysis by Product Type

11. Global Insulin Pen Market Analysis 2016-2020 and Forecast 2021-2031, by Indication
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis by Indication, 2016-2020
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Indication, 2021-2031
11.3.1. Type 1
11.3.2. Type 2
11.4. Market Attractiveness Analysis by Indication

12. Global Insulin Pen Market Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2016-2020
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2021-2031
12.3.1. Hospital Pharmacy
12.3.2. Retail Pharmacy
12.3.3. Online Sales
12.3.4. Diabetes Clinic/Center
12.4. Market Attractiveness Analysis by Distribution Channel

13. Global Insulin Pen Market Analysis 2016-2020 and Forecast 2021-2031, by Region
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Region, 2016-2020
13.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2021-2031
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. East Asia
13.3.5. South Asia
13.3.6. Oceania
13.3.7. Middle East and Africa (MEA)
13.4. Market Attractiveness Analysis By Region

14. North America Insulin Pen Market Analysis 2016-2020 and Forecast 2021-2031
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
14.3.1. By Country
14.3.1.1. U.S.
14.3.1.2. Canada
14.3.2. By Product Type
14.3.3. By Indication
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis

15. Latin America Insulin Pen Market Analysis 2016-2020 and Forecast 2021-2031
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
15.3.1. By Country
15.3.1.1. Brazil
15.3.1.2. Mexico
15.3.1.3. Argentina
15.3.1.4. Rest of Latin America
15.3.2. By Product Type
15.3.3. By Indication
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis

16. Europe Insulin Pen Market Analysis 2016-2020 and Forecast 2021-2031
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
16.3.1. By Country
16.3.1.1. Germany
16.3.1.2. Italy
16.3.1.3. France
16.3.1.4. U.K.
16.3.1.5. Spain
16.3.1.6. Russia
16.3.1.7. Rest of Europe
16.3.2. By Product Type
16.3.3. By Indication
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis

17. South Asia Insulin Pen Market Analysis 2016-2020 and Forecast 2021-2031
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Thailand
17.3.1.3. Indonesia
17.3.1.4. Malaysia
17.3.1.5. Rest of South Asia
17.3.2. By Product Type
17.3.3. By Indication
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis

18. East Asia Insulin Pen Market Analysis 2016-2020 and Forecast 2021-2031
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
18.3.1. By Country
18.3.1.1. China
18.3.1.2. Japan
18.3.1.3. South Korea
18.3.1.4. Rest of East Asia
18.3.2. By Product Type
18.3.3. By Indication
18.3.4. By Distribution Channel
18.4. Market Attractiveness Analysis
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis

19. Oceania Insulin Pen Market Analysis 2016-2020 and Forecast 2021-2031
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
19.3.1. By Country
19.3.1.1. Australia
19.3.1.2. New Zealand
19.3.2. By Product Type
19.3.3. By Indication
19.3.4. By Distribution Channel
19.4. Market Attractiveness Analysis
19.5. Key Market Participants - Intensity Mapping
19.6. Drivers and Restraints - Impact Analysis

20. Middle East and Africa Insulin Pen Market Analysis 2016-2020 and Forecast 2021-2031
20.1. Introduction
20.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
20.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
20.3.1. By Country
20.3.1.1. GCC Countries
20.3.1.2. South Africa
20.3.1.3. Rest of Middle East and Africa
20.3.2. By Product Type
20.3.3. By Indication
20.3.4. By Distribution Channel
20.4. Market Attractiveness Analysis
20.5. Key Market Participants - Intensity Mapping
20.6. Drivers and Restraints - Impact Analysis

21. Key and Emerging Countries Insulin Pen Market Analysis 2016-2020 and Forecast 2021-2031
21.1. Introduction
21.1.1. Market Value Proportion Analysis, By Key Countries
21.1.2. Global Vs. Country Growth Comparison
21.2. U.S. Insulin Pen Market Analysis
21.2.1. By Product Type
21.2.2. By Indication
21.2.3. By Distribution Channel
21.3. Canada Insulin Pen Market Analysis
21.3.1. By Product Type
21.3.2. By Indication
21.3.3. By Distribution Channel
21.4. Mexico Insulin Pen Market Analysis
21.4.1. By Product Type
21.4.2. By Indication
21.4.3. By Distribution Channel
21.5. Brazil Insulin Pen Market Analysis
21.5.1. By Product Type
21.5.2. By Indication
21.5.3. By Distribution Channel
21.6. U.K. Insulin Pen Market Analysis
21.6.1. By Product Type
21.6.2. By Indication
21.6.3. By Distribution Channel
21.7. Germany Insulin Pen Market Analysis
21.7.1. By Product Type
21.7.2. By Indication
21.7.3. By Distribution Channel
21.8. France Insulin Pen Market Analysis
21.8.1. By Product Type
21.8.2. By Indication
21.8.3. By Distribution Channel
21.9. Italy Insulin Pen Market Analysis
21.9.1. By Product Type
21.9.2. By Indication
21.9.3. By Distribution Channel
21.10. Spain Insulin Pen Market Analysis
21.10.1. By Product Type
21.10.2. By Indication
21.10.3. By Distribution Channel
21.11. BENELUX Insulin Pen Market Analysis
21.11.1. By Product Type
21.11.2. By Indication
21.11.3. By Distribution Channel
21.12. Russia Insulin Pen Market Analysis
21.12.1. By Product Type
21.12.2. By Indication
21.12.3. By Distribution Channel
21.13. China Insulin Pen Market Analysis
21.13.1. By Product Type
21.13.2. By Indication
21.13.3. By Distribution Channel
21.14. Japan Insulin Pen Market Analysis
21.14.1. By Product Type
21.14.2. By Indication
21.14.3. By Distribution Channel
21.15. South Korea Insulin Pen Market Analysis
21.15.1. By Product Type
21.15.2. By Indication
21.15.3. By Distribution Channel
21.16. India Insulin Pen Market Analysis
21.16.1. By Product Type
21.16.2. By Indication
21.16.3. By Distribution Channel
21.17. ASEAN Insulin Pen Market Analysis
21.17.1. By Product Type
21.17.2. By Indication
21.17.3. By Distribution Channel
21.18. Australia Insulin Pen Market Analysis
21.18.1. By Product Type
21.18.2. By Indication
21.18.3. By Distribution Channel
21.19. New Zealand Insulin Pen Market Analysis
21.19.1. By Product Type
21.19.2. By Indication
21.19.3. By Distribution Channel
21.20. GCC Countries Insulin Pen Market Analysis
21.20.1. By Product Type
21.20.2. By Indication
21.20.3. By Distribution Channel
21.21. Turkey Insulin Pen Market Analysis
21.21.1. By Product Type
21.21.2. By Indication
21.21.3. By Distribution Channel
21.22. South Africa Insulin Pen Market Analysis
21.22.1. By Product Type
21.22.2. By Indication
21.22.3. By Distribution Channel

22. Market Structure Analysis
22.1. Market Analysis by Tier of Companies
22.2. Market Concentration
22.3. Market Share Analysis of Top Players
22.4. Market Presence Analysis
22.4.1. By Regional Foot Print of Players
22.4.2. Product Foot Print by Players
22.4.3. Channel Foot Print by Players

23. Competition Analysis
23.1. Competition Dashboard
23.2. Competition Benchmarking
23.3. Competition Deep Dive
23.3.1. NovoNordisk A/S
23.3.2. Overview
23.3.2.1. Product Portfolio
23.3.2.2. Analyst Commentary
23.3.2.3. Key Financials
23.3.2.4. Recent Developments
23.3.2.5. Sales Footprint
23.3.2.6. Strategy Overview
23.3.2.6.1. Marketing Strategy
23.3.2.6.2. Product Strategy
23.3.2.6.3. Channel Strategy
23.3.3. Sanofi
23.3.3.1. Product Portfolio
23.3.3.2. Analyst Commentary
23.3.3.3. Key Financials
23.3.3.4. Recent Developments
23.3.3.5. Sales Footprint
23.3.3.6. Strategy Overview
23.3.3.6.1. Marketing Strategy
23.3.3.6.2. Product Strategy
23.3.3.6.3. Channel Strategy
23.3.4. Eli Lilly
23.3.4.1. Product Portfolio
23.3.4.2. Analyst Commentary
23.3.4.3. Key Financials
23.3.4.4. Recent Developments
23.3.4.5. Sales Footprint
23.3.4.6. Strategy Overview
23.3.4.6.1. Marketing Strategy
23.3.4.6.2. Product Strategy
23.3.4.6.3. Channel Strategy
23.3.5. Diamesco Co., Ltd.
23.3.5.1. Product Portfolio
23.3.5.2. Analyst Commentary
23.3.5.3. Key Financials
23.3.5.4. Recent Developments
23.3.5.5. Sales Footprint
23.3.5.6. Strategy Overview
23.3.5.6.1. Marketing Strategy
23.3.5.6.2. Product Strategy
23.3.5.6.3. Channel Strategy
23.3.6. Emperra GmbH E-Health Technologies
23.3.6.1. Product Portfolio
23.3.6.2. Analyst Commentary
23.3.6.3. Key Financials
23.3.6.4. Recent Developments
23.3.6.5. Sales Footprint
23.3.6.6. Strategy Overview
23.3.6.6.1. Marketing Strategy
23.3.6.6.2. Product Strategy
23.3.6.6.3. Channel Strategy
23.3.7. BigFoot Biomedical, Inc.
23.3.7.1. Product Portfolio
23.3.7.2. Analyst Commentary
23.3.7.3. Key Financials
23.3.7.4. Recent Developments
23.3.7.5. Sales Footprint
23.3.7.6. Strategy Overview
23.3.7.6.1. Marketing Strategy
23.3.7.6.2. Product Strategy
23.3.7.6.3. Channel Strategy
23.3.8. Medtronic plc
23.3.8.1. Product Portfolio
23.3.8.2. Analyst Commentary
23.3.8.3. Key Financials
23.3.8.4. Recent Developments
23.3.8.5. Sales Footprint
23.3.8.6. Strategy Overview
23.3.8.6.1. Marketing Strategy
23.3.8.6.2. Product Strategy
23.3.8.6.3. Channel Strategy
23.3.9. YpsoMed AG
23.3.9.1. Product Portfolio
23.3.9.2. Analyst Commentary
23.3.9.3. Key Financials
23.3.9.4. Recent Developments
23.3.9.5. Sales Footprint
23.3.9.6. Strategy Overview
23.3.9.6.1. Marketing Strategy
23.3.9.6.2. Product Strategy
23.3.9.6.3. Channel Strategy
23.3.10. DUKADA Aps
23.3.10.1. Product Portfolio
23.3.10.2. Analyst Commentary
23.3.10.3. Key Financials
23.3.10.4. Recent Developments
23.3.10.5. Sales Footprint
23.3.10.6. Strategy Overview
23.3.10.6.1. Marketing Strategy
23.3.10.6.2. Product Strategy
23.3.10.6.3. Channel Strategy
23.3.11. Insulet Corporation
23.3.11.1. Product Portfolio
23.3.11.2. Analyst Commentary
23.3.11.3. Key Financials
23.3.11.4. Recent Developments
23.3.11.5. Sales Footprint
23.3.11.6. Strategy Overview
23.3.11.6.1. Marketing Strategy
23.3.11.6.2. Product Strategy
23.3.11.6.3. Channel Strategy
23.3.12. Tandem Diabetes Care, Inc.
23.3.12.1. Product Portfolio
23.3.12.2. Analyst Commentary
23.3.12.3. Key Financials
23.3.12.4. Recent Developments
23.3.12.5. Sales Footprint
23.3.12.6. Strategy Overview
23.3.12.6.1. Marketing Strategy
23.3.12.6.2. Product Strategy
23.3.12.6.3. Channel Strategy
23.3.13. Abbott Laboratories
23.3.13.1. Product Portfolio
23.3.13.2. Analyst Commentary
23.3.13.3. Key Financials
23.3.13.4. Recent Developments
23.3.13.5. Sales Footprint
23.3.13.6. Strategy Overview
23.3.13.6.1. Marketing Strategy
23.3.13.6.2. Product Strategy
23.3.13.6.3. Channel Strategy
23.3.14. BIOCORP
23.3.14.1. Product Portfolio
23.3.14.2. Analyst Commentary
23.3.14.3. Key Financials
23.3.14.4. Recent Developments
23.3.14.5. Sales Footprint
23.3.14.6. Strategy Overview
23.3.14.6.1. Marketing Strategy
23.3.14.6.2. Product Strategy
23.3.14.6.3. Channel Strategy
23.3.15. Insulcloud S.L.
23.3.15.1. Product Portfolio
23.3.15.2. Analyst Commentary
23.3.15.3. Key Financials
23.3.15.4. Recent Developments
23.3.15.5. Sales Footprint
23.3.15.6. Strategy Overview
23.3.15.6.1. Marketing Strategy
23.3.15.6.2. Product Strategy
23.3.15.6.3. Channel Strategy

24. Assumptions and Acronyms Used

25. Research Methodology
Note: Product cover images may vary from those shown
  • NovoNordisk A/S
  • Sanofi
  • Eli Lilly
  • Diamesco Co., Ltd.
  • Emperra GmbH E-Health Technologies
  • BigFoot Biomedical, Inc.
  • Medtronic plc
  • YpsoMed AG
  • DUKADA Aps
  • Insulet Corporation
  • Tandem Diabetes Care, Inc.
  • Abbott Laboratories
  • BIOCORP
  • Insulcloud S.L.
Note: Product cover images may vary from those shown